Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent reported Q3 2026 revenue of $725.4 million, up 11% sequentially, and adjusted EBITDA of $34.3 million, up 22%; its medical expense ratio improved 220 basis points to 93%. The company reiterated full-year revenue guidance of $2.6 billion–$2.7 billion and raised adjusted EBITDA guidance to $130 million–$135 million from $120 million–$135 million; management said the midpoint of its 2027 adjusted EBITDA outlook remains at least $150 million. Growth and efficiency drivers include expanded oncology contracts and AI-assisted authorization reviews, while Medicaid-related membership attrition, other client attrition, and a $776 million net-debt balance remain considerations; management is targeting up to $50 million of debt reduction by year-end.

Analysis

The key issue is earnings quality, not the sequential growth rate. Q3’s margin improvement came partly from favorable claims run-out and contractual adjustments; management says some expected Q4 benefit arrived early. That makes the raised FY EBITDA range credible near term, but not yet proof of a durable underlying margin step-up. February’s 2027 outlook should separate recurring contract maturation and automation savings from claims timing and scope changes.

The equity’s upside case rests on turning AuthIntelligence efficiency into retained margin and new business. But savings are shared with clients, and management’s market-share opportunity is still prospective; verify deployed volume, realized cost per review, and renewal economics before capitalizing the announced automation metrics. Oncology concentration also creates bargaining and execution risk: a launch delay, payer scope change, or weaker membership could disproportionately affect the growth narrative.

Balance-sheet risk is the constraint on multiple expansion. Net debt of $776 million is roughly 5.7–6.0x the FY EBITDA guidance midpoint, a rough comparison rather than a covenant measure. With only $10–20 million of expected annual operating cash flow after interest and $26–28 million of capex, the targeted debt reduction needs funding and timing scrutiny; it should not be treated as evidence of self-funded deleveraging. Refinancing terms over the next 12–24 months may matter as much as operating delivery.

Near term, the print and higher EBITDA guide are supportive, but a smaller Q4 MER improvement limits extrapolation. Over 1–3 months, watch cash conversion, claims development, and refinancing disclosure; over 6–18 months, Medicaid attrition, contract maturity, and AI monetization determine whether earnings growth converts to lower leverage. The contrarian risk is that investors price the $150 million 2027 EBITDA midpoint as secured while policy assumptions, membership, scope, and funding remain unresolved.

Key Decisions for Investors

• Do not chase the earnings beat solely on Q3 MER. Treat EVH as a conditional, catalyst-driven long only if February guidance supports the 2027 EBITDA target with identifiable recurring savings and cash conversion; size for elevated leverage risk.
• Set a watch alert for refinancing terms and the source of the planned debt reduction. Reassess negatively if liquidity falls materially, refinancing raises the cost of debt, or management cannot reconcile debt paydown with operating cash flow and capex.
• Track quarterly MER and claims run-out separately. A reversal of favorable development, or failure to deliver the expected Q4 step-up, would weaken the earnings-quality thesis.
• Verify AuthIntelligence adoption and economics at renewals: deployed review volume, manual-touch reduction, client savings share, and realized operating-cost declines. Treat management’s market-share and margin claims as upside until evidenced in reported results.
• Falsifiers for the bullish case include a lower 2027 EBITDA outlook, material Medicaid or exchange membership attrition, adverse contract scope changes, delayed launches, or refinancing that worsens leverage flexibility.